Education
About Us
Working with TipRanks
Follow Us
Kamada (KMDA)
NASDAQ:KMDA
Earnings Data
Report Date
Nov 12, 2025Before Open (Confirmed)
Period Ending
2025 (Q3)Consensus EPS Forecast
0.09Last Year’s EPS
0.07Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call reflects a generally positive outlook for Kamada with strong revenue and EBITDA growth, increased financial guidance, and successful strategic initiatives such as biosimilar launches and plasma center expansion. However, challenges like the decrease in gross profit margin and tax rate fluctuations present areas to monitor.Company Guidance -
Q3 2025
Strong Revenue and EBITDA Growth
Total revenues for the first half of 2025 were $88.8 million, representing an 11% year-over-year increase, and adjusted EBITDA was $22.5 million, up 35% year-over-year. Revenue for the second quarter was $44.8 million, up 5% over the prior year quarter, and adjusted EBITDA was $10.9 million, up 20% year-over-year.
Positive Outlook and Increased Guidance
Based on positive outlook, Kamada is increasing its adjusted EBITDA guidance to between $40 million to $44 million and reiterating its annual revenue guidance of $178 million to $182 million. This represents an increase of approximately 12% in revenues and approximately 23% in adjusted EBITDA over 2024 results.
Innovative Post-Marketing Research Program for CYTOGAM
Initiation of a comprehensive post-marketing research program for CYTOGAM aimed at demonstrating advantages in CMV disease management, potentially leading to additional organic growth.
Successful Biosimilar Launches
Following the successful biosimilar launch in Israel last year, Kamada anticipates launching 2 additional biosimilars later this year, aiming for annual sales of $15 million to $20 million within the next 5 years.
FDA Approval for Plasma Collection Center
U.S. FDA approved a new plasma collection center in Houston, Texas, with an annual collection capacity of approximately 50,000 liters of plasma, expected to generate annual revenues of between $8 million to $10 million at full capacity.
KMDA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
KMDA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Aug 13, 2025 | $7.48 | $7.38 | -1.34% |
May 14, 2025 | $6.89 | $7.05 | +2.32% |
Mar 05, 2025 | $6.42 | $6.90 | +7.48% |
Nov 13, 2024 | $6.10 | $5.86 | -3.93% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Kamada (KMDA) report earnings?
Kamada (KMDA) is schdueled to report earning on Nov 12, 2025, Before Open (Confirmed).
What is Kamada (KMDA) earnings time?
Kamada (KMDA) earnings time is at Nov 12, 2025, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is KMDA EPS forecast?
KMDA EPS forecast for the fiscal quarter 2025 (Q3) is 0.09.